Hematologic malignancies include various diseases that develop from hematopoietic stem cells of bone marrow or lymphatic organs. Currently, conventional DNA-damage-based chemotherapy drugs are approved as standard therapeutic regimens for these malignancies. Although many improvements have been made, patients with relapsed or refractory hematological malignancies have a poor prognosis. Therefore, novel and practical therapeutic approaches are required for the treatment of these diseases. Interestingly several studies have shown that targeting Wee1 kinase in the Hematological malignancies, including AML, ALL, CML, CLL, DLBCL, BL, MCL, etc., can be an effective therapeutic strategy. It plays an essential role in regulating the cell cycle process by abrogating the G2–M cell-cycle checkpoint, which provides time for DNA damage repair before mitotic entry. Consistently, Wee1 overexpression is observed in various Hematological malignancies. Also, in healthy normal cells, repairing DNA damages occurs due to G1-S checkpoint function; however, in the cancer cells, which have an impaired G1–S checkpoint, the damaged DNA repair process depends on the G2–M checkpoint function. Thus, Wee1 inhibition could be a promising target in the presence of DNA damage in order to potentiate multiple therapeutic drugs. This review summarized the potentials and challenges of Wee1 inhibition combined with other therapies as a novel effective therapeutic strategy in Hematological malignancies.

血液系统恶性肿瘤包括由骨髓或淋巴器官的造血干细胞发展而来的各种疾病。目前，传统的基于DNA损伤的化疗药物被批准作为这些恶性肿瘤的标准治疗方案。尽管已经取得了许多进展，但复发或难治性血液恶性肿瘤患者的预后较差。因此，需要新颖且实用的治疗方法来治疗这些疾病。有趣的是，多项研究表明，针对血液恶性肿瘤（包括 AML、ALL、CML、CLL、DLBCL、BL、MCL 等）靶向 Wee1 激酶可能是一种有效的治疗策略。它通过消除 G2-M 细胞周期检查点在调节细胞周期过程中发挥重要作用，该检查点为有丝分裂进入之前的 DNA 损伤修复提供了时间。一致地，在各种血液恶性肿瘤中观察到 Wee1 过度表达。此外，在健康的正常细胞中，G1-S 检查点功能会修复 DNA 损伤；然而，在 G1-S 检查点受损的癌细胞中，受损的 DNA 修复过程取决于 G2-M 检查点功能。因此，在 DNA 损伤存在的情况下，Wee1 抑制可能是一个有希望的靶标，以增强多种治疗药物的作用。这篇综述总结了 Wee1 抑制与其他疗法联合作为血液恶性肿瘤的新型有效治疗策略的潜力和挑战。